Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 07.09.2026 3 Anticancer Res 3 BMC Cancer 1 Br J Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 1 Cancer Sci 1 Chest 1 Clin Cancer Res 3 Clin Lung Cancer 1 Clin Nucl Med 2 Int J Oncol 2 Int J Radiat Oncol Biol Phys 1 J Natl Cancer Inst 2 J Thorac Cardiovasc Surg 6 J Thorac Oncol 12 Lung Cancer 1 Lung Cancer (Auckl) 1 Mol Carcinog 2 N Engl J Med 2 Oncogene 1 Oncologist 4 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. KONDO Y, Fukuyama T, Sonoda D, Tamagawa S, et al
   Association Between Kita-Kyushu Lung Cancer Antigen-1 Positivity and Pathological High-grade Lung Adenocarcinoma.
   Anticancer Res. 2026;46:5045-5054.
   PubMed         Abstract available
   
   
2. ENDO M, Fukuda Y, Nakagawa M, Ogawa K, et al
   Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation.
   Anticancer Res. 2026;46:5155-5167.
   PubMed         Abstract available
   
   
3. RADES D, Streubel MK, Doehring L, Lomidze D, et al
   Physical Activity During a Course of Radiotherapy for Lung Cancer - Results of the APART-LUNG Study.
   Anticancer Res. 2026;46:5129-5140.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. ZHANG R, Li Y, Duan F, Wang X, et al
   PET/CT Radiomics-based assessment of tumor heterogeneity for predicting immunotherapy outcomes in advanced lung squamous cell carcinoma: a retrospective prognostic modeling study.
   BMC Cancer. 2026;26:1041.
   PubMed         Abstract available
   
   
5. LIU J, Wang L, Xia X, Chen S, et al
   Differential predictive value of inflammation- and coagulation-based composite biomarkers for venous thromboembolism and mortality in patients with NSCLC receiving immune checkpoint inhibitors.
   BMC Cancer. 2026;26:1051.
   PubMed         Abstract available
   
   
6. XUE B, Liu Y, Cai M, Gu L, et al
   A weakly supervised deep learning-based recurrence prediction and risk stratification of lung adenocarcinoma from pathology whole-slide images.
   BMC Cancer. 2026;26:1035.
   PubMed         Abstract available
   
   

   
   Br J Cancer

7. CHEN F, Chen Y, Sun W, Ma H, et al
   Correction: Anti-PDGFRalpha autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-kappaB signaling pathway.
   Br J Cancer. 2026 Sep 1. doi: 10.1038/s41416-026-03576.
   PubMed        
   
   

   
   Cancer Epidemiol Biomarkers Prev

8. BOYLE J, Jones RR, White AJ, Zhang JJ, et al
   Creating outdoor air pollution exposome metrics for assessing breast and lung cancer risks in the United States.
   Cancer Epidemiol Biomarkers Prev. 2026 Sep 1. doi: 10.1158/1055-9965.EPI-26-0493
   PubMed         Abstract available
   
   

   
   Cancer Res

9. POMEROY AE, Palmer AC
   Varying Cancer Drug Doses to Balance Tumor Control and Resistance Evolution.
   Cancer Res. 2026;86:4195-4196.
   PubMed         Abstract available
   
   

   
   Cancer Sci

10. ONOYAMA I, Hardy WR, Takeishi S, Zhu LJ, et al
    Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3.
    Cancer Sci. 2026;117:2397-2412.
    PubMed         Abstract available
    
    

    
    Chest

11. GORANTLA N, Dee EC, Willmann J, Jay G Feliciano E, et al
    The impact of national health systems on lung cancer mortality.
    Chest. 2026 Aug 29:S0012-3692(26)06477-9. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

12. MOURI A, Kenmotsu H, Kagamu H, Azuma K, et al
    Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.
    Clin Cancer Res. 2026;32:3880-3890.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

13. MAITY AP, Kjelstrom S, Gu H, Sanborn M, et al
    Assessing Guideline-Directed Care in the New Era of Neoadjuvant Therapy in Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): A Retrospective Review.
    Clin Lung Cancer. 2026;27:8-13.
    PubMed         Abstract available
    
    
14. PARK J, Kang MK, Lee SY, Yoo SS, et al
    Consolidative Hypofractionated Radiotherapy for Oligometastatic Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2026;27:1-7.
    PubMed         Abstract available
    
    
15. MOLLICA L, Tassi E, Copaloni A, De Simone I, et al
    Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 >/= 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.
    Clin Lung Cancer. 2026;27:14-21.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

16. TANG S, Lei Q, Liu Y, Liu Y, et al
    Discordant (1)(8)F-FDG and (6)(8)Ga-DOTATATE PET/CT Findings Before Radionuclide Therapy in Small Cell Lung Cancer.
    Clin Nucl Med. 2026 Sep 4. doi: 10.1097/RLU.0000000000006656.
    PubMed         Abstract available
    
    

    
    Int J Oncol

17. YIMING Z, Jie L
    MicroRNA regulation of macrophage polarization in lung cancer: Regulatory networks and therapeutic potential (Review).
    Int J Oncol. 2026;69:121.
    PubMed         Abstract available
    
    
18. YANG B, Yang Y, Wang W, Wang Y, et al
    Effect of xeroderma pigmentosum group C on the characteristics and regulatory mechanisms of lung cancer stem cells.
    Int J Oncol. 2026;69:120.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

19. CASES C, Latorre-Musoll A, Candela-Juan C, Valduvieco I, et al
    One Year After a Cyberattack: Lessons Learned and Dosimetric Analysis of Contingency Radiotherapy Plans.
    Int J Radiat Oncol Biol Phys. 2026;126:308-317.
    PubMed         Abstract available
    
    
20. MURRAY NZ, Sokeye J, Horns JJ, Chipman J, et al
    Use of Hypofractionation Among Underserved Populations Undergoing Radiation Therapy for Cancer: Implications for Policy.
    Int J Radiat Oncol Biol Phys. 2026;126:301-307.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

21. WANG X, Long JB, Rothen J, Aremu AO, et al
    Matched targeted therapy use after broad genomic profiling in advanced Non-Small cell lung cancer.
    J Natl Cancer Inst. 2026 Sep 1:djag310. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

22. NAKAMURA M, Goto T, Koike T, Tanaka T, et al
    Three-dimensional computed tomography volumetry and pulmonary function outcomes after segmentectomy versus lobectomy.
    J Thorac Cardiovasc Surg. 2026;172:731-741.
    PubMed         Abstract available
    
    
23. HARPOLE D, Heymach JV, Reck M, Taube J, et al
    Clinical outcomes by type of surgery with perioperative durvalumab in patients with resectable non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2026 Sep 3:S0022-5223(26)01288.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

24. ABOLFATHI H, Maranda-Robitaille M, Lamaze FC, Kordahi M, et al
    Integrating Histologic Descriptors Into the Ninth Edition TNM Staging Improves Prognostic Stratification of Lung Adenocarcinoma.
    J Thorac Oncol. 2026;21:103895.
    PubMed         Abstract available
    
    
25. HAYASHI H, Cho BC, Spigel DR, Girard N, et al
    Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
    J Thorac Oncol. 2026;21:103894.
    PubMed         Abstract available
    
    
26. PAREDES DE LA FUENTE R, Borea R, Enrico D, Santana K, et al
    Pulmonary Toxicities of Antibody-Drug Conjugates in Small Cell and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.
    J Thorac Oncol. 2026 Aug 31:104177. doi: 10.1016/j.jtho.2026.104177.
    PubMed         Abstract available
    
    
27. WAISSENGRIN B, Tagliamento M, Sankar K, Reckamp KL, et al
    The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective.
    J Thorac Oncol. 2026;21:103957.
    PubMed         Abstract available
    
    
28. ZHANG YZ, Nicholson AG
    Incorporation of Nonanatomic Histologic Factors Into a Staging System for Lung Cancer: Now Is the Time?
    J Thorac Oncol. 2026;21:103982.
    PubMed        
    
    
29. ZHANG JT, Chen KZ, Gao X, Huang C, et al
    LAMPAD: An Integrated Circulating Tumor DNA-Based Model for Predicting Potential Cure in Patients With Resected NSCLC.
    J Thorac Oncol. 2026;21:103729.
    PubMed         Abstract available
    
    

    
    Lung Cancer

30. AK G, Metintas S, van Zandwijk N, Metintas M, et al
    Environmental asbestos exposure and lung cancer burden compared with mesothelioma in rural Turkiye: A 33-Year population-based cohort study.
    Lung Cancer. 2026;220:109592.
    PubMed         Abstract available
    
    
31. DERVIS M, Burade A, Lanuti M, Dagogo-Jack I, et al
    Utility of artificial intelligence for identifying thoracic lymphadenopathy in lung cancer.
    Lung Cancer. 2026;220:109596.
    PubMed         Abstract available
    
    
32. MOUNTZIOS G, Lammers PE, Sun L, Cho BC, et al
    Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
    Lung Cancer. 2026;220:109581.
    PubMed         Abstract available
    
    
33. WANG Y, Li G, Wang W, Zhang H, et al
    IL20RB drives non-small cell lung cancer progression and immune evasion via K267?dependent activation of JAK2 phosphorylation and STAT3 signaling.
    Lung Cancer. 2026;220:109599.
    PubMed         Abstract available
    
    
34. SAMAMI E, Sarkar S, Zaidi M, Poghosyan H, et al
    Determinants of lung cancer screening intention among eligible individuals.
    Lung Cancer. 2026;220:109540.
    PubMed         Abstract available
    
    
35. YANG Y, Jiang W, Yang G, Li W, et al
    First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial.
    Lung Cancer. 2026;220:109589.
    PubMed         Abstract available
    
    
36. HATANO H, Yoshida T, Higashiyama RI, Shirasawa M, et al
    Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer.
    Lung Cancer. 2026;220:109604.
    PubMed         Abstract available
    
    
37. YOU M, Pan Y, Sun C, Fu L, et al
    Adjuvant immunotherapy in resectable non-small cell lung cancer with nodal downstaging.
    Lung Cancer. 2026;220:109601.
    PubMed         Abstract available
    
    
38. HUMBERT D, Buisson A, Basset M, Toffart AC, et al
    Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.
    Lung Cancer. 2026;220:109594.
    PubMed         Abstract available
    
    
39. OLIVEIRA R, Halvorsen T, Killingberg K, Emdal EF, et al
    Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes.
    Lung Cancer. 2026;221:109606.
    PubMed         Abstract available
    
    
40. PEZZUTO F, Vedovelli L, Maggioni G, Fortarezza F, et al
    Artificial intelligence-based assessment of tumor bed stroma in non-small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study.
    Lung Cancer. 2026;221:109605.
    PubMed         Abstract available
    
    
41. JABER G, Raffoul C, Diab T, Sinno S, et al
    Corrigendum to "EML4-ALK fusion in small cell lung cancer: clinical and molecular insights from a rare case" [Lung Cancer 202 (2025) 108497].
    Lung Cancer. 2026 Sep 4:109595. doi: 10.1016/j.lungcan.2026.109595.
    PubMed        
    
    

    
    Lung Cancer (Auckl)

42. LEVINKRON O, Manickavasagar T, Popat S, Scawn R, et al
    Unilateral Scleral Icterus as a Rare Presentation of Choroidal Metastasis in Transdifferentiated EGFR-Mutant Lung Cancer: A Case Report and Review of the Literature.
    Lung Cancer (Auckl). 2026;17:604360.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

43. FANG Y, Wu W, Wen M, Li D, et al
    E3 Ubiquitin Ligase MDM2 Contributes to Proliferation, Migration/Invasion, Epithelial-Mesenchymal Transition, and Glycolytic Reprogramming in Lung Cancer via Ubiquitinating and Degrading MYH11 Protein.
    Mol Carcinog. 2026 Aug 31. doi: 10.1002/mc.70172.
    PubMed         Abstract available
    
    

    
    N Engl J Med

44. ARBOUR KC, Punekar S, Luo J, Johnson M, et al
    Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2026;395:882-893.
    PubMed         Abstract available
    
    
45. CALLISTER MEJ, Silvestri GA
    Pulmonary Nodules.
    N Engl J Med. 2026;395:894-905.
    PubMed         Abstract available
    
    

    
    Oncogene

46. JIANG Q, Liu Y, Sun W, Liu Z, et al
    HERC4 synergizes with USP16 to promote lung adenocarcinoma growth by augmenting protein translation via stabilizing RPS15.
    Oncogene. 2026;45:3828-3841.
    PubMed         Abstract available
    
    
47. VARADHARAJ V, Leon F, Krishna Kumar N, Nallasamy P, et al
    Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis.
    Oncogene. 2026;45:3858-3873.
    PubMed         Abstract available
    
    

    
    Oncologist

48. GARIAZZO E, Colamartini F, Cantale O, Mogavero A, et al
    EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study).
    Oncologist. 2026;31:oyag285.
    PubMed         Abstract available
    
    

    
    PLoS One

49. GANIE SM, Dutta Pramanik PK, Zhao Z
    Lung cancer risk prediction using interpretable ensemble models on lifestyle and clinical data.
    PLoS One. 2026;21:e0357291.
    PubMed         Abstract available
    
    
50. CUI A, Shi A, Deng L, Sun Y, et al
    Nintedanib in the prevention of radiation-induced lung injury in patients with unresectable stage II-III NSCLC: A protocol for a randomized, multicenter, control group study.
    PLoS One. 2026;21:e0356205.
    PubMed         Abstract available
    
    
51. LEGRAND J, Decoux A, Duron L, Di-Rocco C, et al
    CT radiomics-histopathological correlation for mediastinal lymph node staging in non-small cell lung cancer.
    PLoS One. 2026;21:e0355650.
    PubMed         Abstract available
    
    
52. RAHMAN MN, Hossin AY, Talukder SMI, Siddika MS, et al
    Computational identification and evaluation of Adenium obesum phytochemicals as potential EGFR inhibitors for targeted therapy against non-small-cell lung cancer.
    PLoS One. 2026;21:e0357096.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum